Advanced Biologic Laboratories (ABL), a Luxembourg-based global health information technology company dedicated to deliver healthcare products and services to enable its customers to optimize their HIV healthcare services, has signed a non-exclusive international distribution agreement (excluding United States, Australia, Canada and the United Kingdom) to incorporate Virco BVBA's virco^®TYPE HIV-1 resistance interpretation system into ABL's electronic medical record and decision support system, TherapyEdge™.

 

For more information on ABL and TherapyEdge™ please go to: www.therapyedge.com and for more information on virco^®TYPE HIV-1, please go to: hiv-resistance-products/vircotype-hiv-1.